Latest statistics and disclosures from Abingworth's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Prosensa Hldgs B V Shs Usd, Paratek Pharmaceuticals, Sientra, Portola Pharmaceuticals, Supernus Pharmaceuticals. These five stock positions account for 72.04% of Abingworth's total stock portfolio.
- Added to shares of these 5 stocks: Paratek Pharmaceuticals (+$49.97M), Sientra (+$36.88M), Proteon Therapeutics (+$20.34M), Lombard Med, Zalicus.
- Started 4 new stock positions in Paratek Pharmaceuticals, Proteon Therapeutics, Sientra, Zalicus.
- Reduced shares in these 1 stocks: Epirus Biopharmaceuticals In.
- Sold out of its positions in Epirus Biopharmaceuticals In.
- As of Dec. 31, 2014, Abingworth has $352.09M in assets under management (AUM). Assets under management grew from a total value of $167.25M to $352.09M.
- Independent of market fluctuations, Abingworth was a net buyer by $107.95M worth of stocks in the most recent quarter.
Abingworth portfolio companies for December 2014 quarter
|Ticker||Name||Portfolio Weight||Change||Share Count||Price||Last Trade|
|Prosensa Hldgs B V Shs Usd||33.09||6213924||18.75||0.00|
Past 13F-HR SEC Filings for Abingworth
- Abingworth 2014 Q3 amended - filed Nov. 25, 2014
- Abingworth 2014 Q1 - filed May 21, 2014
- Abingworth 2013 Q2 - filed Aug. 14, 2013
- Abingworth 2013 Q1 - filed May 15, 2013
- Abingworth 2012 Q4 - filed Feb. 13, 2013
- Abingworth 2012 Q3 - filed Nov. 7, 2012
- Abingworth 2012 Q1 - filed May 14, 2012
- Abingworth 2011 Q4 - filed Feb. 7, 2012
- Abingworth 2011 Q3 - filed Nov. 14, 2011
- Abingworth 2011 Q1 - filed May 13, 2011
- Abingworth 2010 Q4 - filed Feb. 14, 2011